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Abstract
Purpose To compare [18F]-fluorodeoxyglucose (FDG) and [18F]-sodium fluoride (NaF) positron emission tomography/
computed tomography (PET/CT) with whole-body magnetic resonance with diffusion-weighted imaging (WB-MRI), for endo-
crine therapy response prediction at 8 weeks in bone-predominant metastatic breast cancer.
Patients and methods Thirty-one patients scheduled for endocrine therapy had up to five bone metastases measured [FDG, NaF
PET/CT: maximum standardized uptake value (SUVmax);WB-MRI: median apparent diffusion coefficient (ADCmed)] at baseline
and 8 weeks. To detect the flare phenomenon, a 12-week NaF PET/CTwas also performed if 8-week SUVmax increased. A 25%
parameter change differentiated imaging progressive disease (PD) from non-PD and was compared to a 24-week clinical
reference standard and progression-free survival (PFS).
Results Twenty-two patients (median age, 58.6 years, range, 40–79 years) completing baseline and 8-week imaging were
included in the final analysis.
Per-patient % change in NaF SUVmax predicted 24-week clinical PD with sensitivity, specificity and accuracy of 60, 73.3, and
70%, respectively. For FDG SUVmax the results were 0, 100, and 76.2% and for ADCmed, 0, 100 and 72.2%, respectively.
PFS < 24weeks was associated with% change in SUVmax (NaF: 41.7 vs. 0.7%, p = 0.039; FDG: − 4.8 vs. − 28.6%, p = 0.005)
but not ADCmed (− 0.5 vs. 10.1%, p = 0.098). Interlesional response heterogeneity occurred in all modalities and NaF flare
occurred in seven patients.
Conclusions FDG PET/CT and WB-MRI best predicted clinical non-PD and both FDG and NaF PET/CT predicted PFS <
24 weeks. Lesional response heterogeneity occurs with all modalities and flare is common with NaF PET/CT.
Keywords Whole-body MRI . Diffusion-weighted MRI . [18F]-fluorodeoxyglucose . [18F]-sodium fluoride . Positron emission
tomography/computed tomography . Bonemetastases
Introduction
Bone metastases in patients with advanced breast cancer are
common, occurring in at least 70% of patients with advanced
disease, and cause significant morbidity [1]. Patients with
breast cancer and bone metastases have a relatively long sur-
vival compared to other cancers and coupled with the associ-
ated morbidity, there are significant implications for
healthcare costs [2, 3]. Despite improved therapeutics, re-
sponse rates are generally less than 50% and so accurate and
timely treatment response-assessment methods are essential
for optimal management [4]. However, it is recognized that
there is an unmet clinical need for correct categorization of
treatment response versus non-response in skeletal metastases
at an early time point as conventional methods, e.g., RECIST
1.1 measurements on computed tomography (CT) ormagnetic
resonance imaging (MRI), usually classify skeletal metastases
as non-measurable disease [5, 6]. Similarly, the isotope bone
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scan is considered to have poor sensitivity and specificity for
detecting early response or non-response [7]. This means that
without an objective early measure of non-response, patients
with bone-predominant metastatic disease may continue with
ineffective treatment longer than necessary, delaying thera-
peutic transition to second or third-line treatment and expos-
ing them to unnecessary treatment-related side effects.
There is increasing evidence that functional imaging
methods may be able to address this need with reported
studies evaluating individual modalities. There is greatest
supporting evidence for [18F]-fluorodeoxyglucose (FDG)
positron emission tomography/computed tomography
(PET/CT) measuring reduction in glucose metabolism in
responding metastases [8–12]. There is relatively little ev-
idence for alternative imaging methods, which nevertheless
show promise in breast cancer or other cancers, including
[18F]-sodium fluoride (NaF) PET/CT [13–17] and whole-
body MRI including diffusion-weighted sequences (WB-
MRI) [18–20]. NaF uptake is dependent on altered blood
flow and mineralization in the metastatic bone microenvi-
ronment [21] and WB-MRI measures changes in the diffu-
sivity of water molecules within tumors [20]. There is no
good comparative evidence of significant superiority of any
of these methods in measuring treatment response and no
clear guidance on the preferred imaging technique in clin-
ical practice [6].
Our hypothesis was that the three functional imaging
methods, WB-MRI, FDG, and NaF PET/CT, can detect func-
tional and metabolic changes in breast cancer skeletal metas-
tases as early as 8 weeks after commencing endocrine-based
therapy. The aims were to measure baseline parameters and
endocrine therapy related changes with each method, to deter-
mine the accuracy of each method to predict progressive dis-
ease (PD), or non-PD compared to a clinical reference stan-
dard, and to determine if the magnitude of change in any
method after 8 weeks of treatment was associated with
progression-free survival (PFS).
Patients and methods
This prospective study received research ethics committee
approval and all patients gave signed informed consent.
Thirty-one patients over the age of 18 with histologically
confirmed breast cancer, with either de-novo or progressive
bone-predominant metastatic disease scheduled for new en-
docrine therapy, were recruited. Patients who were also
scheduled for radiotherapy or colony-stimulating factors
were excluded due to potential effects on functional imag-
ing parameters.
All patients underwent standard follow-up with clinical
assessments including a pain inventory [22], blood tests, in-
cluding serum alkaline phosphatase and tumor marker CA15–
3, and standard imaging, including bone scintigraphy and/or
diagnostic CT. The reference standard for clinical PD or non-
PD was determined by two oncologists (IS and JM, with 10
and 27 years of specialist oncology experience) in consensus
using all the listed clinical assessments up to 24 weeks, or
earlier if there was clinical PD. Patients were categorized as
either having clinical PD or non-PD (stable disease or partial
response) as this is the most relevant dichotomization for clin-
ical management, i.e., continue treatment if non-PD without
treatment toxicity or change treatment if PD [23].
Prior to commencing endocrine therapy, patients
underwent baselineWB-MRI, FDG, and NaF PET/CT, which
were repeated using the same imaging protocol after 8 weeks
of therapy. When an increase in maximum standardized up-
take value (SUVmax) was measured in any bone lesions, a
further 12-week NaF PET/CT scan was performed when pos-
sible to help determine if an early increase in activity was due
to the flare phenomenon, which has been reported with this
tracer [24]. As a flare is not a recognized phenomenon with
WB-MRI or FDG PET/CT, this was not performed with these
modalities. As RECIST 1.1 precludes using CT for measuring
response in bone metastases unless there is a measurable soft
tissue component, we did not include stand-alone CT analysis
in our protocol.
WB-MRI
T1-weighted (T1-W), T2-weighted (T2-W), and diffusion-
weighted (DWI, b-values: 50, 900 s/mm2) axial sequences
were acquired for multiple bed positions from the base of
the skull to upper thighs on a 1.5-T MRI scanner (Siemens
Aera, Erlangen, Germany). Reformatted axial T1-W, T2-
W, DWI b900, and apparent diffusion coefficient (ADC)
map images (5-mm slice thickness and 1.2-mm in-plane
pixel size) were produced for viewing, lesion identifica-
tion, and analysis.
FDG PET/CT
Scans were acquired 60 min after intravenous injection of
FDG (mean 348 ± 18MBq) and all patients had blood glucose
measurements of < 10 mmol/l. Images were acquired from
skull base to upper thighs with 3 min per bed position using
a GE Discovery 710 PET/CT scanner (GE Healthcare,
Chicago, IL, USA). A low-dose CT scan (140 kV, 10 mA,
0.5 s rotation time, and 40-mm collimation) was performed
at the start of imaging to provide attenuation correction and an
anatomical reference. PET images were reconstructed with a
time-of-flight ordered subset expectation maximization algo-
rithm (2 iterations, 24 subsets) with a reconstructed slice thick-
ness of 3.27 mm and pixel size 4.7 mm.
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NaF PET/CT
Scans were acquired 60 min after injection of NaF (mean 228
± 15 MBq). All other acquisition and reconstruction parame-
ters were as for FDG PET/CT.
Scan analysis
Up to five of the largest bone metastases as assessed on the
NaF PET scans were analyzed in each patient by the same
reader (GC), with 25 years of radiology and PET experience,
using the identical lesions in each of the three scan types. For
WB-MRI, lesions were identified on T1-W and T2-W se-
quences and regions drawn on DWI b900, which were auto-
matically mapped to the accompanying ADC images for mea-
surement of the median ADC in mm2/s (ADCmed). A reduc-
tion in ADCmed of > 25% was used to differentiate imaging
PD from imaging non-PD [25, 26]. For FDG and NaF PET/
CT, the same lesions were selected and regions of interest
(ROIs) outlined semi-automatically using a 40% of maximum
activity threshold. The maximum standardized uptake value
(SUVmax) was measured from these regions and a > 25% in-
crease used to differentiate imaging PD from imaging non-PD
[27–29]. Individual lesion ADCmed and SUVmax measure-
ments were recorded for per-lesion analysis and mean values
for each patient recorded for per-patient analysis. Both analy-
ses were performed to obtain clinically relevant results on a
per-patient basis that can be used in management decisions
and also to report on intra-patient response heterogeneity, a
topic of interest in oncology and an observation that may
impact on treatment decisions. Intra-patient inter-lesional het-
erogeneity of response was defined when a lesion showed a >
25% change that was discordant with the clinical reference
standard for that patient. In NaF PET/CT scans, a flare was
defined in each lesion that showed an initial increase in
SUVmax at 8 weeks that then declined on the 12-week scan.
Statistical methods
It was calculated that 20 patients with baseline and 8-week scans
would give 80% power to predict clinical PD from non-PD 80%
of the time (deemed a clinically useful level) for each modality.
Differences between parameters in patients with clinical PD (PFS
< 24 weeks) versus non-PD were tested for normality and com-
pared using Student’s t test or Mann–WhitneyU test as appropri-
ate. PFS was defined as the time from the first study scan until the
time to clinical progression. Patients who had not progressed clin-
ically at the end of the studywere censored.Relationships between
scans and PFS were tested by comparing scan metrics in patients
with PFS < 24 weeks with those > 24 weeks. Statistical analyses
were conducted using IBM SPSS statistics software (version 24).
A P value of < 0.05 was used for statistical significance.
Results
Patients
Twenty-two patients (median age 58.6, range, 40–79 years)
completed at least one set of both baseline and 8-week imag-
ing (18 all three modalities, two FDG alone, one FDG and
NaF and one NaF alone) and hence WB-MRI: 18 patients, 76
lesions; FDG PET/CT: 21 patients, 90 lesions; NaF PET/CT:
20 patients, 85 lesions. Nine patients did not undergo 8-week
imaging (eight due to patient choice and one required radio-
therapy for incipient cord compression). Six patients had de
novo metastatic disease and 16 had progressive disease prior
to recruitment and apart from two patients who had small
volume lung and liver metastases; all patients had only skele-
tal metastases. Endocrine therapy consisted of letrozole (n =
12), exemestane with everolimus (n = 6), tamoxifen (n = 3),
and famotidine (n = 1). Bisphosphonates (zoledronic acid,
n = 11 or ibandronate, n = 4) or denosumab (n = 7), were used
as adjunctive therapy. By the clinical reference standard up to
24 weeks, five patients had PD and 17 patients had non-PD.
Median PFS was 10.3 months (2.6–47.5 months) with 15
patients alive at the end of the study when censored.
NaF PET/CT
There was a significant difference in % change in SUVmax
between patients with clinical PD (PFS < 24 weeks) and non-
Table 1 Performance of %
changes in WB-MRI, FDG PET/
CT and NaF PET/CT parameters
in predicting clinical progressive
disease up to 24 weeks on a per-
patient and per-lesion basis
Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
WB-MRI per patient 0 100 0 72.2 72.2
WB-MRI per lesion 15 96.4 60 76.1 75
FDG PET/CT per patient 0 100 0 76.2 76.2
FDG PET/CT per lesion 5 97.1 33.3 78.2 76.7
NaF PET/CT per patient 60 73.3 42.9 84.6 70.0
NaF PET/CT per lesion 55 83.1 50 85.7 76.5
WB-MRI whole-body magnetic resonance with diffusion-weighted imaging, FDG [18 F]-fluorodeoxyglucose,
NaF [18 F]-sodium fluoride, PET/CT positron emission tomography/computed tomography
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PD on a per-patient analysis (41.7 vs. 0.7%, p = 0.039) and on a
per-lesion analysis (44.4 vs. − 2.6%, p = 0.001). Of the 20 pa-
tients, 11 showed a less than 25% increase in SUVmax and were
concordant with the clinical reference standard of non-PD.
Three out of the five patients with clinical PD showed > 25%
increase in SUVmax (Table 1, Fig. 1a). On analysis of the 85
lesions, 54 were concordant with the clinical reference standard
of non-PD and 11 of 20 lesions showed a > 25% increase in
SUVmax in patients with clinical PD (Table 1, Fig. 1b). Baseline
SUVmax was not associated with clinical PD (p = 0.6).
Twelve of the 85 lesions (14.1%) in seven patients
showed discordant changes to the clinical reference stan-
dard and were categorized as showing an inter-lesional
heterogeneous imaging response.
Eighteen lesions (21.2%) in seven patients showed an in-
crease in NaF SUVmax at 8 weeks followed by a subsequent
decrease at 12 weeks, and were therefore categorized as a
flare. Four of these patients had clinical non-PD at 24 weeks.
FDG PET/CT
There was a significant difference in % change in SUVmax be-
tween patients with clinical PD (PFS < 24 weeks) and non-PD
on a per-patient analysis (− 4.8 vs. – 28.6%, p = 0.005) and on a
per-lesion analysis (− 5.0 vs. − 29.7%, p = 0.001). Of the 21
patients, 16 showed < 25% increase in SUVmax and were con-
cordant with the clinical reference standard of non-PD. None of
the five patients with clinical PD showed an increase in
SUVmax > 25% (Table 1, Fig. 1a). On analysis of the 90 indi-
vidual lesions, 68 were concordant with clinical non-PD but
Fig. 1 Waterfall plots showing % change in ADCmed and SUVmax in a
each patient and in b each lesion for (top) WB-MRI, (middle) FDG PET/
CT, and (bottom) NaF PET/CT [clinical non-progressors (blue) and
progressors (red)]. ADC, apparent diffusion coefficient; FDG, [18F]-
fluorodeoxyglucose; NaF, [18F]-sodium fluoride
Fig. 2 a NaF PET maximum intensity projection (MIP) and b
corresponding transaxial images [PET (top), fused PET/CT (middle),
and CT (bottom)] of a lesion in L5 at baseline (left) and 8 weeks (right)
after commencing endocrine therapy in a patient who had a response by
the clinical reference standard. SUVmax of the L5 vertebral lesion
decreased from 42.7 to 32.5
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only one of 20 lesions showed a > 25% increase in SUVmax in
patients with clinical PD (Table 1, Fig. 1b). Baseline SUVmax
was not associated with clinical PD (p = 0.65).
Five of the 90 lesions (5.6%) in four patients showed dis-
cordant changes to the clinical reference standard and were
categorized as showing an inter-lesional heterogeneous imag-
ing response.
WB-MRI
There was no significant difference in % change in ADCmed
between patients with clinical PD (PFS < 24 weeks) and non-
PD on a per-patient analysis (− 0.5 vs. 10.1%, p = 0.098) but
there was on a per-lesion analysis (− 3.2 vs. 9.2%, p = 0.012). Of
the 18 patients, 13 showed less than a 25% decrease in ADCmed
and were concordant with the clinical reference standard of non-
PD. None of the five patients with clinical PD showed a > 25%
decrease in ADCmed (Table 1, Fig. 1a). On analysis of the 76
individual lesions, 54 were concordant with clinical non-PD but
only three of 20 lesions in patients with clinical PD showed a
> 25% decrease in ADCmed (Table 1, Fig. 1b). There was no
difference in baseline ADCmed (p = 0.46) between patients with
PFS < 24 weeks compared to PFS > 24 weeks.
Two of the 76 lesions (2.6%) in two patients showed dis-
cordant changes to the clinical reference standard and were
categorized as showing an inter-lesional heterogeneous imag-
ing response. Representative NaF, FDG PET, and WB-MRI
images from a patient who showed a response by the clinical
reference standard are illustrated in Figs. 2, 3, and 4,
respectively.
Discussion
Recognizing the limitations of conventional imaging in
predicting treatment response in skeletal metastases and
the increasing adoption of novel functional imaging into
oncologic practice, it is timely to directly compare three
contending functional imaging methods in this role. We
have shown in this cohort of bone-predominant metastatic
breast cancer patients treated with endocrine therapy that
changes in parameters that reflect tumor cellularity (DWI),
tumor glucose metabolism (FDG PET/CT), and the bone
microenvironment (NaF PET/CT), can be detected and
quantified. All three modalities showed a similar overall
accuracy in predicting PD/non-PD as determined by a clin-
ical reference standard that used conventional clinical,
blood, and imaging methods up to 24 weeks. In addition,
significant differences were seen in the magnitude of pa-
rameter change in those with PFS < 24 weeks compared to
those with longer PFS, for NaF, and FDG PET/CT.
While FDG PET/CT and WB-MRI performed well in
predicting non-PD, which would allow patients to continue
with therapy [26], the magnitude of change (reduction in
SUVmax or increase in ADCmed) on a per-patient or per-
lesion basis was greater with FDG (Fig. 1). However, nei-
ther WB-MRI nor FDG PET/CT predicted PD at this early
8-week time point. Both FDG PET/CT and WB-MRI pri-
marily reflect tumor cell effects (glucose metabolism [30]
and restriction in water molecule motion influenced by cel-
lularity and other tumor-related factors [31], respectively)
and while these demonstrated > 25% changes in less than
8 weeks in many responding metastases, the biological
changes associated with tumor progression were not of suf-
ficient magnitude to be detected this early at this threshold,
implying a non-linear relationship between changes in im-
age parameters and clinical PD.
Nevertheless, a significant difference in % change of
FDG SUVmax was seen between patients with PFS
< 24 weeks and those with longer PFS but with no signifi-
cant difference in ADCmed, implying % change in FDG
SUVmax may be a better prognostic metric. Our findings
augment previous reports where FDG PET/CT SUVmax
has previously been shown to be associated with PFS in
skeletal, nodal, or visceral metastases from breast cancer
[8, 9] or to be associated with changes in tumor markers
[10, 11]. To our knowledge, no literature exists for response
prediction or assessment using WB-MRI in skeletal metas-
tases from breast cancer in humans. Preclinical data, using a
breast cancer model treated with the antiangiogenic agent
bevacizumab, rather than endocrine treatment or chemo-
therapy, found DWI to be insensitive [32]. However, sev-
eral small series report an increase in ADC in responding
prostate cancer bone metastases [19, 20, 33].
While NaF PET/CT feasibility has previously been shown
for monitoring treatment response in breast cancer bone me-
tastases [13], to our knowledge definitive results have only
been shown in prostate cancer [14–17]. In our series, NaF
PET/CT showed modest sensitivity for predicting clinical
PD (three of five patients). However, the clinical utility of
NaF would be limited, as imaging PD would not be able to
be differentiated from a treatment-induced flare, as observed
in some of our patients. Despite these observations, the results
for NaF PET/CT are of academic interest and suggest that the
bone microenvironment changes reflected by this tracer are
more rapid and larger in amplitude than the changes we saw
with tumor cellular processes demonstrated by FDG PET/CT
and WB-MRI.
We observed a heterogeneous response betweenmetastases
most frequently with NaF PET/CT, predominantly reflecting
Fig. 3 a FDG PET MIP and b corresponding transaxial images [PET
(top), fused PET/CT (middle), and CT (bottom)] of a lesion in L5 at
baseline (left) and 8 weeks (right) in the same patient as Figs. 2 and 4.
SUVmax of the L5 vertebral lesion decreased from 9.9 to 4.9
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the flare phenomenon seen with this tracer. Some inter-
lesional response heterogeneity was also observed with FDG
PET/CT (5.6%) andWB-MRI (2.6%), suggesting that biolog-
ical response heterogeneity exists and may reflect tumor resis-
tance to therapy in some clones.
This study has some potential limitations. Additional test–
retest scans were not performed for measurement of repeatabil-
ity as the imaging protocol was already intensive for patients
and as good repeatability and inter-observer variation have pre-
viously been reported for all three imaging methods employed
in this study [19, 25, 26, 28, 29, 34]. Partly due to the intensity
of the protocol, nine patients did not complete any 8-week
imaging and a small number of patients did not undergo all
three imaging tests. This led to a lower number of evaluable
patients than preferred but nevertheless, enabled a comparison
between all threemodalities inmost patients and a large number
of metastases (n = 90) were included in the analysis. We
adopted previously published thresholds of 25% change in im-
age metrics to differentiate PD from non-PD but using alterna-
tive thresholds would not have significantly improved the abil-
ity to differentiate in this series with 25% appearing to be a
satisfactory level cross the three modalities. Potential limita-
tions with the clinical reference standard we employed were
offset by using consensus from two blinded oncologists and
allowing all standard clinical, blood, and imaging to be includ-
ed while allowing up to 24 weeks for assessment in a method
we have previously shown to be robust [35]. While specific
treatments differed slightly between patients, they were all
endocrine-based regimens without chemotherapy or other
non-endocrine treatment-based regimes in order to minimize
any heterogeneity due to different classes of treatment as was
practically possible. Finally, we have only tested the imaging
metrics in breast cancer patients undergoing endocrine-based
therapy and we cannot exclude different biological effects from
other therapeutic regimes, e.g., chemotherapy, that could affect
imaging parameters differently.
Conclusions
Changes in tumor cell characteristics and bone microenviron-
ment can be measured with functional imaging methods in
bone-predominant metastatic breast cancer at 8 weeks after
commencing endocrine-based therapy, although the amplitude
of changes did not always reach the threshold for response
categorization. Overall accuracy in predicting PD is similar
between the three tested modalities but FDG PET/CT and
WB-MRI are more reliable than NaF PET/CT in determining
non-PD at 8weeks. Given the larger quantitative percent chang-
es in FDG SUVmax compared to ADCmed and the fact that
larger percent changes in FDG SUVmax are associated with
PFS, this method has an advantage for determining non-PD
and would allow an early decision for patient therapy to con-
tinue if there were no limiting side effects. In contrast, none of
the three methods were reliable at 8 weeks in predicting subse-
quent clinical PD, NaF PET/CT performing best with a sensi-
tivity of 60%. However, a flare and inter-lesional heterogeneity
is relatively common at 8 weeks with NaF PET/CTand because
of these factors, this method would not be sufficiently reliable
to change a patient’s treatment at 8 weeks.
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